Category: Diabetes
Poster Session III
Patients with gestational diabetes mellitus (GDM) are at risk for developing type-2 DM. Pregnancy and the postpartum period are a window of opportunity for medical intervention which may improve patients’ future health. The standard recommendation following GDM is a 75-gram oral glucose tolerance test (OGTT) 6-12 weeks postpartum. At our hospital, fasting glucose (FG) is obtained from all parturients with GDM 24-48 hours postpartum. We sought to compare the correlation between the postpartum FG value and the results of the OGTT 6-12 weeks postpartum.
Study Design:
We reviewed computerized medical records of all patients with a diagnosis of GDM who gave birth at our institution during 2021, and performed an OGTT 6-12 weeks postpartum. We examined the strength of FG as a predictor for an abnormal OGTT.
Results: A total of 319 patients met our inclusion criteria. FG was normal in 261 cases (82%), and abnormal in 58 (18%). Most patients had a normal OGTT (229, 72%), however, postpartum OGTT was abnormal in 90 patients (28%). Of them, 84 (93%) were diagnosed with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), and only 6 patients (7%) were found to have overt DM. A univariate analysis showed a significant correlation between abnormal FG and pathological postpartum OGTT (p=0.001, Pearson’s correlation 0.186). A multivariate analysis also demonstrated FG as a good predictor for IFG or IGT with an adjusted odds ratio (OR) of 1.028 (p=0.048, CI 1.000-1.056). FG as a predictor for overt DM had an adjusted OR of 1.126 (p=0.012, CI 1.026-1.235). Postpartum FG had modest sensitivity for IGT and for DM (31% and 33% respectively). However, the specificity was high for both (87% and 82% respectively), with a negative predictive value (NPV) of 76% for IGF or IGT and 98% for DM.
Conclusion:
Fasting glucose 24-48 hours postpartum is a good predictor of a pathological OGTT 6-12 weeks postpartum. As the compliance for completing an OGTT is low, we may consider using FG as a tool for predicting future DM.
Hadas Zafrir danieli, MD
Resident
Rabin Medical Center
Petach Tikva, HaMerkaz, Israel
Shay Sukenik, MD, MHA
Rabin Medical Center
Petach Tikva, HaMerkaz, Israel
Sarah Dollinger, MD, MHA
Rabin Medical Center
Petach Tikva, HaMerkaz, Israel
Dror Weinberg Almog, MD (she/her/hers)
Rabin Medical Center
Petach Tikva, HaMerkaz, Israel
Or Berchovich, MD
Rabin Medical Center
Petach Tikva, HaMerkaz, Israel
Eran Hadar, Prof.
Helen Schneider Hospital for Women, Rabin Medical Center
Kfar Sirkin, HaMerkaz, Israel
Alexandra Berezowsky, MD
Women Hospital, Rabin Medical Center
Petach Tikva, Israel, Israel